These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 7847834)

  • 1. In vitro activity of titanocenedichloride versus cisplatin and doxorubicin in primary and recurrent epithelial ovarian cancer.
    Kurbacher CM; Mallmann P; Kurbacher JA; Sass G; Andreotti PE; Rahmun A; Hübner H; Krebs D
    Anticancer Res; 1994; 14(5A):1961-5. PubMed ID: 7847834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of titanocenedichloride in human renal cell carcinoma compared to conventional antineoplastic agents.
    Kurbacher CM; Nagel W; Mallmann P; Kurbacher JA; Sass G; Hübner H; Andreotti PE; Krebs D
    Anticancer Res; 1994; 14(4A):1529-33. PubMed ID: 7979181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of titanocenedichloride versus cisplatin in four ovarian carcinoma cell lines evaluated by a microtiter plate ATP bioluminescence assay.
    Kurbacher CM; Bruckner HW; Andreotti PE; Kurbacher JA; Sass G; Krebs D
    Anticancer Drugs; 1995 Oct; 6(5):697-704. PubMed ID: 8845481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma.
    Andreotti PE; Cree IA; Kurbacher CM; Hartmann DM; Linder D; Harel G; Gleiberman I; Caruso PA; Ricks SH; Untch M
    Cancer Res; 1995 Nov; 55(22):5276-82. PubMed ID: 7585588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity of drug resistance in human breast and ovarian cancers.
    Kern DH
    Cancer J Sci Am; 1998; 4(1):41-5. PubMed ID: 9467045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay.
    Untch M; Sevin BU; Perras JP; Angioli R; Untch A; Hightower RD; Koechli O; Averette HE
    Gynecol Oncol; 1994 Apr; 53(1):44-9. PubMed ID: 7909786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
    Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
    Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer].
    Qian XL; Peng ZL; Liu SL
    Ai Zheng; 2003 Dec; 22(12):1352-4. PubMed ID: 14693068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
    Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
    O'Meara AT; Sevin BU
    Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
    Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Lele SB; Marchetti DL; Baker TR; Blumenson LE
    Gynecol Oncol; 1998 Sep; 70(3):392-7. PubMed ID: 9790793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The evaluation of adenosine triphosphate bioluminescence assay for chemosensitivity testing of ovarian cancer cell line].
    Shi W; Gu M; Liang L
    Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):79-82. PubMed ID: 8758798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties, and in vitro antitumor activity.
    Ronconi L; Giovagnini L; Marzano C; Bettìo F; Graziani R; Pilloni G; Fregona D
    Inorg Chem; 2005 Mar; 44(6):1867-81. PubMed ID: 15762713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
    Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
    Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivatives.
    Moebus VJ; Stein R; Kieback DG; Runnebaum IB; Sass G; Kreienberg R
    Anticancer Res; 1997; 17(2A):815-21. PubMed ID: 9137413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma.
    Tewari KS; Mehta RS; Burger RA; Yu IR; Kyshtoobayeva AS; Monk BJ; Manetta A; Berman ML; Disaia PJ; Fruehauf JP
    Gynecol Oncol; 2005 Sep; 98(3):360-8. PubMed ID: 16000215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer.
    Hille S; Rein DT; Riffelmann M; Neumann R; Sartorius J; Pfützner A; Kurbacher CM; Schöndorf T; Breidenbach M
    Anticancer Drugs; 2006 Oct; 17(9):1041-4. PubMed ID: 17001177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.